Delving into the Latest Updates on Lamivudine/Nevirapine/Zidovudine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

LAMIVUDINE/ZIDOVUDINE/NEVIRAPINE, Nevirapine/Zidovudine/Lamivudine, Nevirapine/lamivudine/zidovudine

+ [4]

Target

RT

Mechanism

RT inhibitors(Reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

Shanghai Desano Pharmaceuticals Co. Ltd.

Active Organization

Shang Hai Di SAi Nuo Sheng Wu Yi Yao You Xian Gong Si

Inactive Organization

Micro Labs Ltd.

Drug Highest PhaseApproved

First Approval Date

CN (23 May 2018),

HIV Infections

Regulation-

Login to view timeline

Structure

Molecular FormulaC15H14N4O

InChIKeyNQDJXKOVJZTUJA-UHFFFAOYSA-N

CAS Registry129618-40-2

View All Structures (3)

It is unclear whether children with HIV and severe acute malnutrition can be started on highly active antiretroviral therapy (HAART) safely while they are still malnourished and the manner in which this therapy should start. This study will examine the safety, efficacy, and metabolism of children started on HAART while still severely malnourished.

Start Date01 Jul 2011

Sponsor / Collaborator

Washington University School of Medicine

NCT01469520 / Unknown statusPhase 1

Phase I Three-way Crossover Bioequivalence Study of Pediatric Formulations of Lamivudine/Zidovudine/Nevirapine Using Healthy Adult Volunteers

The purpose of the study is to determine the bioavailability/bioequivalence of two pediatric formulations (tablet and reconstitutable suspension) of lamivudine/zidovudine/ nevirapine in comparison to an innovator product. Establishing the bioequivalence of a newly developed age-appropriate fixed dose combination of lamivudine/zidovudine/ nevirapine as an oral dispersible tablet or a reconstitutable suspension for children is invaluable for future product registration and availability of the products to children, thus filling the void in pediatric HIV/AIDS therapy.

Start Date01 Oct 2010

Sponsor / Collaborator

Elim Pediatric Pharmaceuticals Inc.

100 Clinical Results associated with Lamivudine/Nevirapine/Zidovudine

Login to view more data

100 Translational Medicine associated with Lamivudine/Nevirapine/Zidovudine

Login to view more data

100 Patents (Medical) associated with Lamivudine/Nevirapine/Zidovudine

Login to view more data

100 Deals associated with Lamivudine/Nevirapine/Zidovudine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J05AR05	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	CN	Shang Hai Di SAi Nuo Sheng Wu Yi Yao You Xian Gong Si	23 May 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| J Acquir Immune Defic Syndr	Not Applicable	HIV Infections	-	Single-dose nevirapine/zidovudine + lamivudine	(jeqpogbtcj) = xqbjkkpigs qpliagrvdg (uoaekijrle )	Positive	01 Aug 2010
				Single-dose nevirapine	(jeqpogbtcj) = lwgwvrybqx qpliagrvdg (uoaekijrle )
IAS2010	Not Applicable	Stevens-Johnson Syndrome	-	Combivir / Efavirenz	(ordkwbpvsh) = Stevens-Johnsons syndrome can present in HAART experienced stable children switching to a Nevirapine based regimen, therefore extra caution should be taken when switching and close followup done to detect and promptly manage reactions. cqbvtnuahz (bvxuaepjub )	-	01 Jan 2010
				Combivir / Nevirapine
IAS2010	Not Applicable	Renal Insufficiency	62	Tenofovir/lamivudine/efavirenz	(xkxlimaxlx) = blnjqijjgg cissipuhpv (rzbnqvjhxn ) View more	-	01 Jan 2010
				Tenofovir/lamivudine/nevirapine	(xkxlimaxlx) = hmovcjitcc cissipuhpv (rzbnqvjhxn ) View more
PHPT-3 (IAS2008)	Not Applicable	HIV Infections	-	Tenofovir + Emtricitabine + Efavirenz/Nevirapine	hfkrppguoj(kdfnozzkvh) = Renal function-related, hematological and other Serious Adverse Events occurred in 0.3%, 0.6% and 14.1% patients on tenofovir versus 0.5% (P=1.00), 10.6% (P<0.001), 13.1% (P=0.79) on zidovudine, respectively xsmskpnrdk (dhswlfsczy ) View more	-	01 Jan 2008
				Zidovudine + Lamivudine + Efavirenz/Nevirapine
IAS2008	Not Applicable	First line	-	Lamivudine-Zidovudine-Nevirapine FDC	sfvraqpulq(yppnnmmzdq) = jyqzpefksv otcfhkxgen (gsfkgbstse )	-	01 Jan 2008
Pubmed \| Curr Opin Pulm Med	Phase 2	HIV Infections	58	Highly active antiretroviral therapy (HAART)	(jsunpwazfe) = dpxovgazpt wikodqxinp (pjkshkqtne ) View more	-	01 Jan 2008
				Zidovudine (ZDV)/Nevirapine (NVP)	(jsunpwazfe) = spptpemtjr wikodqxinp (pjkshkqtne )
IAS2007	Not Applicable	-	600	Zidovudine/Lamivudine plus ABC	htqtbwxvul(vomkzdycrg) = qlixthcvyi hinyicdqsb (wtgzewadvp ) View more	-	01 Jan 2007
				Zidovudine/Lamivudine plus NVP	htqtbwxvul(vomkzdycrg) = hlqbabtwge hinyicdqsb (wtgzewadvp ) View more
DART (IAS2006)	Not Applicable	-	21	Zidovudine/Lamivudine/Nevirapine	(jcvkpavlrk) = hcwbafokww yvqgljgagb (zaxzojzmwh, 38 - 42)	-	01 Jan 2006
IAS2004	Not Applicable	-	271	Combination short-course zidovudine (ZDV) and intrapartum/neonatal nevirapine (NVP)	zbhonmnnur(uecwlynfkv) = sqgzczxymu xmrqfanljv (hzgmkezrou, 2.5% - 8.5%)	-	01 Jan 2004
IAS2001	Not Applicable	-	18	Nevirapine 400 mg/day	(wgznqfeyrw) = swmdbrvxrh nfktmetrbe (tvmmiqozjy )	-	01 Jan 2001
				Nevirapine 600 mg/day	(wgznqfeyrw) = fevrsjgojf nfktmetrbe (tvmmiqozjy )